By Fineline Cube 
Vicebio Ltd has entered into an exclusive, definitive agreement to be acquired by France-based major Sanofi (NASDAQ: SNY) . Under the terms of the agreement, Vicebio shareholders will receive up to a total of USD 1.6 billion. This includes an upfront payment of USD 1.15 billion and development and regulatory milestones payments of USD 450 million.
Vicebio’s Technology and Pipeline
Vicebio is a biopharmaceutical company focused on developing next-generation vaccines against respiratory viral infections. The company utilizes its proprietary Molecular Clamp technology, discovered at The University of Queensland. This technology uniquely stabilizes viral glycoproteins to elicit strong protective immune responses and enables high-yield production for ready-to-use liquid multivalent formulations.
Clinical Trial Progress
Vicebio is currently conducting an exploratory Phase 1 clinical trial with its lead asset VXB-241, a bivalent vaccine targeting both RSV and hMPV viruses. Interim analysis of the Phase 1 study has demonstrated a favorable safety and tolerability profile in adults aged 60 and above.-Fineline Info & Tech